Working… Menu

Phase 3, Randomized, Safety, Lot Consistency and Clinical Benefit Study of Recombinant Botulinum Vaccine A/B (rBV A/B)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01940315
Recruitment Status : Withdrawn (Sponsor decision due to product manufacturing and redesign of clinical trial.)
First Posted : September 12, 2013
Last Update Posted : December 4, 2018
Information provided by (Responsible Party):
DynPort Vaccine Company LLC, A GDIT Company

No Study Results Posted on for this Study
Study was withdrawn before participants were enrolled.
Recruitment Status : Withdrawn
Estimated Primary Completion Date : March 2019
Estimated Study Completion Date : September 2019